Eganelisib alone or with chemo for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug called eganelisib, either alone or with the chemotherapy drug cytarabine, for people with relapsed or refractory acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It aims to see if the drug is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML or high-risk MDS with at least 10% blasts in your bone marrow.
- You have a good performance status (able to care for yourself and out of bed more than half the day).
- Your liver and kidneys are working well (confirmed by blood tests within the last week).
- You have not had a stem cell transplant in the last 6 months.
- You are not taking strong immune-suppressing drugs or steroids (except for adrenal insufficiency).
- Any infection or fever must be under control, and your white blood cell count must be 25,000 or lower before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.